This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Minerva Neurosciences’s 8K filing here.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
Further Reading
- Five stocks we like better than Minerva Neurosciences
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- 2 Stocks to Gain From Trump Universal Tariffs on Critical Imports
- Buy P&G Now, Before It Sets A New All-Time High
- Rigetti Computing, Inc.: Buy, Sell, or Hold for 2025
- The 3 Best Fintech Stocks to Buy Now
- Delta Can Fly to New Highs in 2025; Here’s Why
